Efficacy, Safety, and Tolerability of a Wearable Electrotrichogenic Device in Men with Androgenetic Alopecia: A Randomized, Double-Blind, Sham-Controlled Trial [0.03%]
穿戴式电毛发生发仪治疗男性雄激素性脱发的疗效、安全性和耐受性：随机双盲对照试验
Carlos A Chacón-Martínez,Gleb Pogorelov,Kin K Cabral et al.
Carlos A Chacón-Martínez et al.
Introduction: Androgenetic alopecia (AGA), the most common form of hereditary hair loss, is highly prevalent and commonly requires long-term, consistent treatment. This randomized controlled trial evaluated the efficacy, ...
Real-World Use of Baricitinib in Patients with Atopic Dermatitis in Spain: DAMA-S Study, A Retrospective Chart Review [0.03%]
巴利昔맙治疗西班牙特应性皮炎患者的真实世界研究（DAMA-S研究）：一项回顾性病历分析
Enrique Gómez de la Fuente,Enrique Herrera,Iñigo Martinez-Espronceda Esquerdo et al.
Enrique Gómez de la Fuente et al.
Introduction: Baricitinib has shown positive results in clinical trials both from efficacy and safety outcomes; however, there is still a need to further understand its use in routine practice in Spain. ...
Beyond the Skin: Assessing Itch in Atopic Dermatitis - Insights from UK Dermatologists. A Cross-Sectional Survey and Narrative Review [0.03%]
超越表象：英国皮肤科医生对特应性皮炎患者瘙痒的评估见解——横断面调查与叙述性综述
Philip Laws,Alberto Barea,Georgina Fremlin et al.
Philip Laws et al.
Background: Chronic itch is the most burdensome symptom of atopic dermatitis (AD), yet its routine assessment and measurement remain inconsistent. Objecti...
Efficacy and Safety of the PD-1 Agonist JNJ-67484703 in Participants with Atopic Dermatitis: Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial Results [0.03%]
JNJ-67484703（一种用于治疗特应性皮炎受试者的PD-1激动剂）2a期、随机、双盲、安慰剂对照试验疗效和安全性：临床试验结果
Michael Cecchini,Bartlomiej Kwiek,Fang Liu-Walsh et al.
Michael Cecchini et al.
Introduction: Atopic dermatitis (AD) is a chronic, inflammatory skin disease with a high burden and unmet needs. Herein, we have assessed the efficacy and safety of JNJ-67484703, a programmed cell death protein 1 (PD-1)-a...
Multidisciplinary Management in Psoriasis: A Structured Approach for Early Comorbidity Detection and Referral [0.03%]
银屑病的多学科管理：早期共病检测和转诊的结构化方法
Anna López-Ferrer,Álvaro González-Cantero,Ana Gutiérrez-Casbas et al.
Anna López-Ferrer et al.
Introduction: Psoriasis is a systemic disease with a high burden of underdiagnosed and undertreated comorbidities, partly due to fragmented care. These comorbidities significantly worsen outcomes and quality of life, high...
Early Proteomic Alterations in Non-segmental Vitiligo Skin Following Treatment with Topical Tacrolimus [0.03%]
他克莫司治疗非节段型白癜风皮损早期蛋白质组改变
Morten B Haulrig,Sonja Kabatnik,Lone Skov et al.
Morten B Haulrig et al.
Introduction: Vitiligo is a chronic depigmenting skin disease that can severely affect quality of life. First-line treatments include topical calcineurin inhibitors such as tacrolimus, but their molecular mechanisms of ac...
Summary of Research: Systemic Treatments in Moderate-to-Severe Atopic Dermatitis in Pediatric Patients up to 12 Years of Age: Real-World Treatment Outcomes from the PEDISTAD Registry [0.03%]
PEDISTAD登记研究的回顾：一项针对12岁以下中重度特应性皮炎患者系统治疗的真实世界疗效观察性研究
Amy S Paller,Danielle Marcoux,Michele Ramien et al.
Amy S Paller et al.
This is a summary of the original article "Systemic Treatments in Moderate-to-Severe Atopic Dermatitis in Pediatric Patients up to 12 Years of Age: Real-World Treatment Outcomes from the PEDISTAD Registry." Atopic dermatitis (AD, or eczema)...
Canadian Treat-to-Target Practice Survey of Real-World Interventions and Strategies in Psoriasis (CAN TARGET PSORIASIS) [0.03%]
加拿大就银屑病治疗目标开展的现实世界干预和策略调查(CAN TARGET PSORIASIS)
Jensen Yeung,Parbeer Grewal,Perla Lansang et al.
Jensen Yeung et al.
Introduction: Treat-to-target (T2T) strategies have been proposed to support decision-making in chronic plaque psoriasis care, but their use in Canadian clinical practice has not been well studied. ...
How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach [0.03%]
巴利昔单抗治疗重度斑秃的理想疗程有多长：循证分析
Brett King,Maryanne Senna,Manabu Ohyama et al.
Brett King et al.
Introduction: Scalp hair regrowth in severe alopecia areata (AA) can occur rapidly or take up to 2 years in some patients. Baseline factors influence the likelihood and/or timing of treatment response with Janus kinase in...
Gestational Diabetes Mellitus Increases the Risk of Atopic Dermatitis in Children: A National Retrospective Study with Analysis by Treatment Modality [0.03%]
妊娠糖尿病会增加儿童患特应性皮炎的风险：按治疗方式分层的全国队列研究
Sarah Weissmann,Nir Amitai,Eliya Honig et al.
Sarah Weissmann et al.
Introduction: Atopic dermatitis (AD) is a common childhood inflammatory disease influenced by genetic and environmental factors. Maternal metabolic conditions, including gestational diabetes mellitus (GDM), may affect off...